LLY

TentativeAI MemoPost-earnings T+3

Eli Lilly and

As of 2026-08-08/Post-earnings T+3/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Action

—

Confidence

high

Horizon

—

Key catalyst

Investment Community Meeting • 2026-12-07

Base target: $1328 / p=50% prob

Biggest risk

The earnings update raises the execution bar. Lilly remains exposed to lower realized prices, sustained dependence on Mounjaro and Zepbound volume, acquired IPR&D charges, regulatory and launch execution, and the possibility that pipeline expectations are already reflected in the stock.

Invalidation

Break below $1025 or thesis failure.

What would change my mind?

Q2 confirmed strong volume-led commercial momentum, higher full-year guidance, continued obesity pipeline progress, and expanding manufacturing capacity. Retatrutide and orforglipron provide additional multi-year optionality.

Research note

Recommendation

—

Confidence

high

As of

2026-08-08

Base target

$1328

p=50%

Bull target

$1475

p=25%

Bear target

$1025

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q2 results and higher 2026 guidance
Retatrutide registration package and planned 2027 filing
Q2 confirmed strong volume-led commercial momentum, higher full-year guidance, continued obesity pipeline progress, and expanding manufacturing capacity.

BearKey bullets

Acquired IPR&D charges and recent business-development activity may create earnings volatility and integration demands.
High expectations make demand, supply, reimbursement, pricing, and launch execution important near-term risks.
Lower realized prices could offset part of continued Mounjaro and Zepbound volume growth.

WatchKey bullets

Investment Community Meeting

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $1328 (p=50%)

Target spread vs base: +11% / -23%

Scenario probabilities

Bull Target: $1475 (p=25%)Base Target: $1328 (p=50%)Bear Target: $1025 (p=25%)

Commentary

The company-source gap is closed by Lilly's August 5 SEC earnings exhibit, which confirmed strong Q2 growth, higher guidance, regulatory progress, retatrutide milestones, and manufacturing investment. A market snapshot on August 7 showed shares at $1,185.71, down 0.58% on the session, but the available evidence does not establish the full earnings-day reaction. No verified post-print analyst revision was found, so sentiment remains constructive but tentative and better framed as monitoring than as a high-conviction chase. [#SEC-8K-2026-08-05]

As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q2 results and higher 2026 guidance
Retatrutide registration package and planned 2027 filing

Scenarios

Bull Target (Scenario probability)

$1475 / p=25% prob

Base Target (Scenario probability)

$1328 / p=50% prob

Bear Target (Scenario probability)

$1025 / p=25% prob

Analysis 2026-08-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.72

Social Sentiment (7d)

Events

Other notable items detected

EVENT2026-12-07
Investment Community Meeting
Lilly has scheduled an Investment Community Meeting for December 7, 2026, providing a dated checkpoint for obesity demand, pipeline progress, manufacturing capacity, and capital allocation. [#SEC-8K-2026-04-30]
Prob 76.00% • Move 5.00% • Priced-in 60.00%

Short-term Catalysts

Next few weeks

Q2 results and higher 2026 guidance
2026-08-05
Lilly reported Q2 2026 revenue of $23.0 billion, up 48%, and raised full-year revenue guidance to $85.0-$87.0 billion. Non-GAAP EPS was $8.38, though acquired IPR&D charges reduced reported and adjusted EPS. [#SEC-8K-2026-08-05]
Prob 85% • Move 4% • Priced-in 85%

Long-term Catalysts

Months to a year

Retatrutide registration package and planned 2027 filing
2027-08-08
Lilly reported positive data from three additional Phase 3 retatrutide trials and said the clinical package is complete to support global registrations, with a U.S. biologics license application planned for Q1 2027. [#SEC-8K-2026-08-05]
Prob 68% • Move 10% • Priced-in 55%

Risks

Acquired IPR&D charges and recent business-development activity may create earnings volatility and integration demands.
High expectations make demand, supply, reimbursement, pricing, and launch execution important near-term risks.
Lower realized prices could offset part of continued Mounjaro and Zepbound volume growth.
Post-print analyst estimate, rating, and target revisions remain unavailable.
Retatrutide, orforglipron, and other pipeline programs remain subject to clinical, regulatory, manufacturing, and commercialization risk.

Peers

Symbol	Summary
AMGN	Large-cap biotech operating peer with substantial cash generation and obesity-pipeline exposure, but less direct commercial GLP-1 momentum than Lilly.
ABBV	Diversified branded-pharma comparator useful for assessing cash-generating franchise support versus Lilly's greater dependence on obesity-category growth.
MRK	Large branded-drug peer for commercial execution and pipeline durability, although its growth drivers are less directly tied to obesity demand.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-08

Loading AI feed…

Symbol

Summary

AMGN

Large-cap biotech operating peer with substantial cash generation and obesity-pipeline exposure, but less direct commercial GLP-1 momentum than Lilly.

ABBV

Diversified branded-pharma comparator useful for assessing cash-generating franchise support versus Lilly's greater dependence on obesity-category growth.

MRK

Large branded-drug peer for commercial execution and pipeline durability, although its growth drivers are less directly tied to obesity demand.